4-(羟基甲基)-3-硝基苯甲酸甲酯 | 89950-93-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(羟基甲基)-3-硝基苯甲酸甲酯
• 英文名称: methyl 4-(hydroxymethyl)-3-nitrobenzoate
• CAS: 89950-93-6
• 化学式: C₉H₉NO₅
• 分子量: 211.174
• InChiKey: VJFYRPYYFMEHPF-UHFFFAOYSA-N

物化性质

• 沸点：
  376.4±32.0 °C(Predicted)
• 密度：
  1.380±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  92.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(羟基甲基)-3-硝基苯甲酸甲酯 在 sodium hydroxide 作用下， 反应 1.0h， 以186 mg的产率得到4-羟甲基-3-硝基苯甲酸
  参考文献：
  名称：

  在聚合物载体上酶促合成寡糖。光敏的取代聚丙烯酰胺珠

  摘要：

  摘要通过在4-羧基-2-硝基苄基β-d-吡喃葡萄糖苷或4-羧基-2-硝基苄基4-O-β-d-吡喃葡萄糖基-之间形成酰胺键，合成了两种感光的葡萄糖和纤维二糖聚合物。 β-d-吡喃葡萄糖苷和氨乙基取代的聚丙烯酰胺凝胶珠。随后，将聚合物用作糖基转移酶（d-半乳糖基转移酶，EC 2.4.1.22）和转糖基酶（溶菌酶，EC 3.4.1.17）活性的受体。作为2-硝基苄基衍生物，这些聚合物在辐照后确实发生了分子内氧化还原（

  DOI：

  10.1016/0008-6215(83)88352-9
• 作为产物：
  描述：

  4-(溴甲基)-3-硝基苯甲酸甲酯 在 氨 、 sodium acetate 作用下， 以 甲醇 为溶剂， 生成 4-(羟基甲基)-3-硝基苯甲酸甲酯
  参考文献：
  名称：

  Disaccharide synthesis on a soluble hyperbranched polymer

  摘要：

  A hyperbranched star polymer was employed as a soluble support for disaccharide synthesis as a practical alternative to a dendrimer support. The large number of terminal groups present on the support permit very high loading levels to be possible. Polymer bound intermediates could be directly analyzed by MALDI-TOF mass spectrometry due to the presence of a photolabile linker that is cleaved by the MALDI-TOF laser. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(99)01709-8

文献信息

• Investigations into the Potential Role of Metabolites on the Anti-Leukemic Activity of Imatinib, Nilotinib and Midostaurin
  作者：Paul W. Manley

  DOI：10.2533/chimia.2019.561

  日期：——

  The efficacy and side-effects of drugs do not just reflect the biochemical and pharmacodynamic properties of the parent compound, but often comprise of cooperative effects between the properties of the parent and active metabolites. Metabolites of imatinib, nilotinib and midostaurin have been synthesised and evaluated in assays to compare their properties as protein kinase inhibitors with the parent drugs. The N-desmethyl-metabolite of imatinib is substantially less active than imatinib as a BCR-ABL1 kinase inhibitor, thus providing an explanation as to why patients producing high levels of this metabolite show a relatively low response rate in chronic myeloid leukaemia (CML) treatment. The hydroxymethylphenyl and N-oxide metabolites of imatinib and nilotinib are only weakly active as BCR-ABL1 inhibitors and are unlikely to play a role in the efficacy of either drug in CML. The 3-(R)-HO-metabolite of midostaurin shows appreciable accumulation following chronic drug administration and, in addition to mutant forms of FLT3, potently inhibits the PDPK1 and VEGFR2 kinases (IC50 values

  药物的功效和副作用不仅仅反映了母化合物的生化和药效特性，而且通常包括母化合物和活性代谢物之间的协同效应。已经合成和评估了伊马替尼、尼洛替尼和米多斯他林的代谢物，以比较它们作为蛋白激酶抑制剂的特性与母药的区别。伊马替尼的N-去甲基代谢物作为BCR-ABL1激酶抑制剂的活性明显低于伊马替尼，这解释了为什么产生高水平该代谢物的患者在慢性髓细胞白血病（CML）治疗中显示相对较低的反应率。伊马替尼和尼洛替尼的羟甲基苯和N-氧代谢物作为BCR-ABL1抑制剂的活性很弱，不太可能在CML中发挥作用。米多斯他林的3-(R)-HO-代谢物在长期用药后显示出明显的积累，并且除了FLT3的突变形式外，还强力抑制PDPK1和VEGFR2激酶（IC50值

• [EN] PYRIDINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV<br/>[FR] COMPOSES PYRIDINES UTILISES COMME INHIBITEURS DE DIPEPTIDYLE PEPTIDASE IV
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2005042488A1

  公开（公告）日：2005-05-12

  A compound represented by the formula wherein R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted hydroxy group; R3 is an optionally substituted aromatic group; R4 is an optionally substituted amino group; L is a divalent chain hydrocarbon group; Q is a bond or a divalent chain hydrocarbon group; and X is a hydrogen atom, a cyano group, a nitro group, an acyl group, a substituted hydroxy group, an optionally substituted thiol group, an optionally substituted amino group or an optionally substituted cyclic group; provided that when X is an ethoxycarbonyl group, then Q is a divalent chain hydrocarbon group. The compound has a peptidase inhibitory action, is useful as an agent for the prophylaxis or treatment of diabetes and the like, and is superior in efficacy, duration of action, specificity, lower toxicity and the like.

  该化合物的化学式表示为其中R1和R2相同或不同，每个都是可选择取代的碳氢基团或可选择取代的羟基团；R3是可选择取代的芳香基团；R4是可选择取代的氨基团；L是二价链状碳氢基团；Q是键或二价链状碳氢基团；X是氢原子、氰基、硝基、酰基、取代的羟基团、可选择取代的硫醇基团、可选择取代的氨基团或可选择取代的环状基团；但当X是乙氧羰基团时，Q为二价链状碳氢基团。该化合物具有肽酶抑制作用，可用作糖尿病等疾病的预防或治疗药物，并在功效、作用持续时间、特异性、毒性较低等方面具有优越性。
• [EN] [6,6] FUSED BICYCLIC HDAC8 INHIBITORS<br/>[FR] INHIBITEURS DE HDAC8 BICYCLIQUE [6,6] FUSIONNÉE
  申请人：FORMA THERAPEUTICS INC

  公开号：WO2017040963A1

  公开（公告）日：2017-03-09

  The present invention is directed to compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R1, R2, R2', L, X, W, Y1,Y2, Y3, and Y4 are described herein.

  本发明涉及以下式I的化合物：及其药用可接受的盐、前药、溶剂合物、水合物、互变异构体、或其同分异构体，其中R1、R2、R2'、L、X、W、Y1、Y2、Y3和Y4如本文所述。
• SUBSTITUTED PYRAZOLE DERIVATIVES
  申请人：ITO Mitsuhiro

  公开号：US20090270359A1

  公开（公告）日：2009-10-29

  The present invention provides a novel pyrazole derivative and an androgen receptor antagonist containing the derivative. The present invention provides a compound represented by the formula (I′) wherein R 1 is a hydrogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom, or a group via a sulfur atom; R 2 is a phenyl group having cyano (the phenyl group may further have substituent(s) other than cyano); R 3 is a hydrogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom, or a group via a sulfur atom; R 4 is a cyclic group optionally having substituent(s); and X is methylene optionally having substituent(s), or CO, or a salt thereof.

  本发明提供一种新型吡唑衍生物和含有该衍生物的雄激素受体拮抗剂。本发明提供一种由下式表示的化合物(I′)：其中R1是氢原子、通过碳原子的基团、通过氮原子的基团、通过氧原子的基团或通过硫原子的基团；R2是苯基，带有氰基（苯基可能还有除氰基之外的取代基）；R3是氢原子、通过碳原子的基团、通过氮原子的基团、通过氧原子的基团或通过硫原子的基团；R4是可选地带有取代基的环状基团；X是亚甲基，可选地带有取代基，或CO，或其盐。
• PRODRUG-TYPE ANTICANCER AGENT USING CANCER-SPECIFIC ENZYMATIC ACTIVITY
  申请人：The University of Tokyo

  公开号：US20200399305A1

  公开（公告）日：2020-12-24

  To provide novel compounds that are promising as prodrug-type anticancer agents, a compound represented by general formula (I) or a salt thereof is provided.

  提供具有前瞻性作为前药型抗癌药物的新化合物，提供了一种由通用式(I)表示的化合物或其盐。